HitGen Inc.

Equities

688222

CNE1000040G3

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
12.64 ^CNY	+2.27%		+3.44%	-15.68%

Apr. 24	HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.

December 29, 2022 at 09:42 pm EST

From October 1, 2022 to December 29, 2022, the company has repurchased 650,700 shares, representing 0.19% for CNY 10.01 million. With this, the company has completed the repurchase of 1,238,700 shares, representing 0.34% for CNY 20 million under the buyback announced on July 1, 2022.

Latest news about HitGen Inc.

HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
HitGen Receives 10 Million Yuan in Government Subsidies	23-09-29	MT
The Structural Genomics Consortium and HitGen Inc. Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	23-09-28	CI
HitGen Inc.(XSSC:688222) added to S&P Global BMI Index	23-09-18	CI
HitGen Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
HitGen Inc. Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics, Inc	23-08-10	CI
HitGen Inc. Launches A Newly Upgraded Version of OpenDELâ„¢, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research	23-06-26	CI
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Certain A Shares of HitGen Inc. are subject to a Lock-Up Agreement Ending on 16-APR-2023.	23-04-15	CI
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.	22-12-29	CI
HitGen Inc.'s Equity Buyback announced on July 1, 2022, has expired with 1,238,700 shares, representing 0.34% for CNY 20 million.	22-12-28	CI
HitGen Inc. Announces Research Agreement with Nitrase Therapeutics, Inc. Focused on DNA-Encoded Library Based Drug Discovery	22-12-11	CI
DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	22-11-13	CI
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
C4X Discovery Holdings plc and HitGen Inc. to Collaborate in Inflammation Hit Identification Project	22-10-20	CI
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.	22-10-10	CI
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.	22-10-10	CI
HitGen Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
LoQus23 Therapeutics Ltd. and Hitgen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	22-07-27	CI
HitGen Inc. announces an Equity Buyback for CNY 30 million worth of its shares.	22-06-30	CI
HitGen Inc. authorizes a Buyback Plan.	22-06-28	CI
Almac Discovery Ltd and HitGen Inc. Announces Strategic Research Collaboration	22-05-20	CI

Chart HitGen Inc.

Duration

Period

More charts

Company Profile

HitGen Inc is a China-based company mainly engaged in the early research and development of original innovative drugs. The Company focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The Company mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The Company conducts its businesses within the domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for HitGen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.64 CNY

Average target price

16 CNY

Spread / Average Target

+26.58%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HITGEN INC.	-15.68%	697M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.38%	21.96B
GENMAB A/S	-8.70%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs